Potential for Point-of-Care Tests to Reduce Chlamydia-associated Burden in the United States: A Mathematical Modeling Analysis

• Published in: Clinical infectious diseases 2020-04, Vol.70 (9), p.1816-1823
• Main Authors: Rönn, Minttu M, Menzies, Nicolas A, Gift, Thomas L, Chesson, Harrell W, Trikalinos, Tom A, Bellerose, Meghan, Malyuta, Yelena, Berruti, Andrés, Gaydos, Charlotte A, Hsu, Katherine K, Salomon, Joshua A
• Format: Article
• Language: English
• Subjects: and Commentaries; Chlamydia Infections - diagnosis; Chlamydia Infections - drug therapy; Chlamydia Infections - epidemiology; Chlamydia trachomatis; Female; Humans; Mass Screening; Pelvic Inflammatory Disease; Point-of-Care Testing; United States - epidemiology
• ISSN: 1058-4838; 1537-6591
• DOI: 10.1093/cid/ciz519

Abstract Background Point-of-care testing (POCT) assays for chlamydia are being developed. Their potential impact on the burden of chlamydial infection in the United States, in light of suboptimal screening coverage, remains unclear. Methods Using a transmission model calibrated to data in the United States, we estimated the impact of POCT on chlamydia prevalence, incidence, and chlamydia-attributable pelvic inflammatory disease (PID) incidence, assuming status quo (Analysis 1) and improved (Analysis 2) screening frequencies. We tested the robustness of results to changes in POCT sensitivity, the proportion of patients getting treated immediately, the baseline proportion lost to follow-up (LTFU), and the average treatment delay. Results In Analysis 1, high POCT sensitivity was needed to reduce the chlamydia-associated burden. With a POCT sensitivity of 90%, reductions from the baseline burden only occurred in scenarios in which over 60% of the screened individuals would get immediate treatment and the baseline LTFU proportion was 20%. With a POCT sensitivity of 99% (baseline LTFU 10%, 2-week treatment delay), if everyone were treated immediately, the prevalence reduction was estimated at 5.7% (95% credible interval [CrI] 3.9–8.2%). If only 30% of tested persons would wait for results, the prevalence reduction was only 1.6% (95% CrI 1.1–2.3). POCT with 99% sensitivity could avert up to 12 700 (95% CrI 5000–22 200) PID cases per year, if 100% were treated immediately (baseline LTFU 20% and 3-week treatment delay). In Analysis 2, when POCT was coupled with increasing screening coverage, reductions in the chlamydia burden could be realized with a POCT sensitivity of 90%. Conclusions POCT could improve chlamydia prevention efforts if test performance characteristics are significantly improved over currently available options. Point-of-care testing (POCT) could improve chlamydia prevention efforts if there is considerable improvement in currently available POCT performance.